Suppr超能文献

通过全外显子组测序鉴定食管鳞状细胞癌中的胚系突变谱

Identification of the Germline Mutation Profile in Esophageal Squamous Cell Carcinoma by Whole Exome Sequencing.

作者信息

Deng Jiaying, Weng Xiaoling, Ye Junyi, Zhou Daizhan, Liu Yun, Zhao Kuaile

机构信息

Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

出版信息

Front Genet. 2019 Feb 18;10:47. doi: 10.3389/fgene.2019.00047. eCollection 2019.

Abstract

Esophageal squamous cell carcinoma (ESCC) is associated with poor prognosis and occurs with high frequency in China. The germline mutation profile in ESCC remains unclear, and therefore, the discovery of oncogenic alterations in ESCC is urgently needed. This study investigates the germline mutation profile and reveals associations among genotype-environment interactions in ESCC. Whole exome sequencing and follow-up analysis were performed in 77 matched tumor-normal ESCC specimens to examine the germline profiles. Additionally, associations among genotype-environment interactions were investigated. We identified 84 pathogenic/likely pathogenic mutations and 51 rare variants of uncertain significance (VUS). Twenty VUS with InterVar evidence of a score of moderate pathogenicity (PM) 2/PM2+ supporting pathogenicity (PP) 1 were found to have pathogenic significance. CYP21A2 was the most frequently mutated gene, and the p.Gln319 variant was identified in 6.5% (5/77) of patients. The TP53 p.V197E mutation, located within the DNA binding domain, was found in 1.3% (1/77) of patients. In total, the 11.7% (9/77) of individuals with homologous recombination (HR) VUS were more likely to have well-differentiated tumors than those without ( = 0.003). The degree of lymph node metastasis was correlated with homologous recombination deficiency (HRD) and VUS group ( < 0.05). Moreover, the 10.4% (8/77) of individuals with mismatch repair (MMR) VUS had a higher tumor mutational burden (TMB), although the correlation was not significant. Our study identified the germline mutation profiles in ESCC, providing novel insights into the molecular pathogenesis of this disease. Our results may also serve as a useful resource for the exploration of the underlying mechanism of ESCC and may provide information for the prevention, diagnosis and risk management of ESCC.

摘要

食管鳞状细胞癌(ESCC)预后较差,在中国发病率较高。ESCC的种系突变谱仍不清楚,因此,迫切需要发现ESCC中的致癌改变。本研究调查了ESCC的种系突变谱,并揭示了基因型-环境相互作用之间的关联。对77对匹配的ESCC肿瘤-正常标本进行了全外显子测序和后续分析,以检查种系谱。此外,还研究了基因型-环境相互作用之间的关联。我们鉴定出84个致病/可能致病的突变和51个意义未明的罕见变异(VUS)。发现20个具有InterVar证据、中等致病性(PM)评分为2/PM2+支持致病性(PP)评分为1的VUS具有致病意义。CYP21A2是最常发生突变的基因,在6.5%(5/77)的患者中鉴定出p.Gln319变异。在1.3%(1/77)的患者中发现了位于DNA结合域内的TP53 p.V197E突变。总体而言,具有同源重组(HR)VUS的个体中有11.7%(9/77)比没有HR VUS的个体更有可能患有高分化肿瘤(P = 0.003)。淋巴结转移程度与同源重组缺陷(HRD)和VUS组相关(P < 0.05)。此外,具有错配修复(MMR)VUS的个体中有10.4%(8/77)的肿瘤突变负担(TMB)较高,尽管相关性不显著。我们的研究确定了ESCC中的种系突变谱,为该疾病的分子发病机制提供了新的见解。我们的结果也可能作为探索ESCC潜在机制的有用资源,并可能为ESCC的预防、诊断和风险管理提供信息。

相似文献

1
Identification of the Germline Mutation Profile in Esophageal Squamous Cell Carcinoma by Whole Exome Sequencing.
Front Genet. 2019 Feb 18;10:47. doi: 10.3389/fgene.2019.00047. eCollection 2019.
2
Whole-exome sequencing reveals critical genes underlying metastasis in oesophageal squamous cell carcinoma.
J Pathol. 2017 Aug;242(4):500-510. doi: 10.1002/path.4925. Epub 2017 Jul 12.
3
Genomic analyses reveal SCN7A is associated with the prognosis of esophageal squamous cell carcinoma.
Esophagus. 2022 Apr;19(2):303-315. doi: 10.1007/s10388-021-00898-y. Epub 2022 Jan 7.
4
Genetic Heterogeneity of Esophageal Squamous Cell Carcinoma with Inherited Family History.
Onco Targets Ther. 2020 Sep 3;13:8795-8802. doi: 10.2147/OTT.S262512. eCollection 2020.
5
Comprehensive Study of Germline Mutations and Double-Hit Events in Esophageal Squamous Cell Cancer.
Front Oncol. 2021 Apr 6;11:637431. doi: 10.3389/fonc.2021.637431. eCollection 2021.
6
An Old Story Retold: Loss of G1 Control Defines A Distinct Genomic Subtype of Esophageal Squamous Cell Carcinoma.
Genomics Proteomics Bioinformatics. 2015 Aug;13(4):258-70. doi: 10.1016/j.gpb.2015.06.003. Epub 2015 Sep 16.
7
Genetic Alterations in Esophageal Tissues From Squamous Dysplasia to Carcinoma.
Gastroenterology. 2017 Jul;153(1):166-177. doi: 10.1053/j.gastro.2017.03.033. Epub 2017 Mar 30.
8
Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing.
World J Gastroenterol. 2016 Feb 21;22(7):2284-93. doi: 10.3748/wjg.v22.i7.2284.
10
Tumor Molecular Testing Guides Anti-PD-1 Therapy and Provides Evidence for Pathogenicity of Mismatch Repair Variants.
Oncologist. 2018 Dec;23(12):1395-1400. doi: 10.1634/theoncologist.2018-0108. Epub 2018 Aug 2.

引用本文的文献

1
Integrative Multi-Omics Approach for Improving Causal Gene Identification.
Genet Epidemiol. 2025 Jan;49(1):e22601. doi: 10.1002/gepi.22601. Epub 2024 Oct 23.
2
Esophageal squamous cell carcinoma in a patient with mutation: a rare association.
Ecancermedicalscience. 2024 Jul 16;18:1730. doi: 10.3332/ecancer.2024.1730. eCollection 2024.
3
Novel Variants of CEP152 in a Case of Compound-Heterozygous Inheritance of Epilepsy.
Glob Med Genet. 2024 Jan 16;11(1):20-24. doi: 10.1055/s-0043-1777807. eCollection 2024 Jan.
4
Esophageal Squamous Cancer from 4NQO-Induced Mice Model: CNV Alterations.
Int J Mol Sci. 2022 Nov 18;23(22):14304. doi: 10.3390/ijms232214304.
6
The novel immune-related genes predict the prognosis of patients with hepatocellular carcinoma.
Sci Rep. 2021 May 21;11(1):10728. doi: 10.1038/s41598-021-89747-7.
7
Comprehensive Study of Germline Mutations and Double-Hit Events in Esophageal Squamous Cell Cancer.
Front Oncol. 2021 Apr 6;11:637431. doi: 10.3389/fonc.2021.637431. eCollection 2021.
9
BReast CAncer (BRCA) gene mutations as an emerging biomarker for the treatment of gastrointestinal malignancies.
Chin Clin Oncol. 2020 Oct;9(5):64. doi: 10.21037/cco-2019-ddp-05. Epub 2020 Aug 10.
10
Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses.
Front Oncol. 2019 Dec 17;9:1433. doi: 10.3389/fonc.2019.01433. eCollection 2019.

本文引用的文献

3
CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2.
J Steroid Biochem Mol Biol. 2017 Nov;174:192-200. doi: 10.1016/j.jsbmb.2017.09.007. Epub 2017 Sep 8.
4
Development of CYP21A2 Genotyping Assay for the Diagnosis of Congenital Adrenal Hyperplasia.
Mol Diagn Ther. 2017 Dec;21(6):663-675. doi: 10.1007/s40291-017-0296-6.
6
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Genome Med. 2017 Apr 19;9(1):34. doi: 10.1186/s13073-017-0424-2.
7
Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.
Gynecol Oncol Res Pract. 2017 Feb 22;4:4. doi: 10.1186/s40661-017-0039-8. eCollection 2017.
8
Cancer statistics in China, 2015.
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.
9
Regulation of Mutant p53 Protein Expression.
Front Oncol. 2015 Dec 17;5:284. doi: 10.3389/fonc.2015.00284. eCollection 2015.
10
Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries.
World J Gastroenterol. 2015 Jul 14;21(26):7933-43. doi: 10.3748/wjg.v21.i26.7933.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验